Videos

The panel discusses a 52-year-old patient with metastatic TNBC including lung lesions and previously treated stable brain metastases, presenting for first-line treatment recommendations.

Panelists agreed that subcutaneous amivantamab represents meaningful progress over the IV formulation, nearly eliminating infusion reactions, reducing dosing frequency to every four weeks, and lowering high-grade dermatologic toxicity, although grade 1-2 rash and the burden of the COCOON prophylaxis regimen remain relevant considerations for patients.

Dr. Hamid presents an 86-year-old retired construction worker with diabetes, hypertension, and prior basal cell carcinoma, now with a 2.8 cm facial CSCC lesion and imaging-confirmed pulmonary metastases.

Dr. Ajai Chari and NP Samantha Shenoy discuss practical aspects of managing newly diagnosed multiple myeloma (NDMM) in routine clinical practice, emphasizing the importance of individualized care throughout the treatment journey. The faculty review strategies for monitoring patients receiving long-term therapy, addressing treatment-related adverse events, and maintaining adherence through proactive supportive care and patient education. The conversation highlights the value of multidisciplinary collaboration, including the role of advanced practice providers in coordinating care, reinforcing treatment expectations, and facilitating shared decision-making. Dr. Chari and NP Shenoy also discuss how ongoing communication with patients can help manage quality-of-life concerns while supporting treatment continuity and long-term disease control. The discussion underscores the importance of integrating clinical trial evidence with practical experience to optimize frontline management and deliver patient-centered care for individuals living with NDMM.

Dr. Ajai Chari and NP Samantha Shenoy conclude the discussion by reflecting on the evolving management of newly diagnosed multiple myeloma (NDMM) and the clinical implications of recent advances in CD38-directed therapy. The faculty summarize how long-term follow-up from contemporary clinical trials has reinforced the importance of achieving deep responses while balancing efficacy, safety, and patient-centered treatment goals. The conversation explores the growing role of minimal residual disease (MRD) assessment, ongoing therapy, and individualized treatment duration as areas of continued clinical interest, while emphasizing that treatment decisions should remain tailored to each patient's overall health status and preferences. Dr. Chari and NP Shenoy also discuss practical considerations for multidisciplinary care, patient education, and longitudinal follow-up, highlighting the importance of shared decision-making as frontline treatment strategies continue to evolve and additional long-term evidence becomes available for patients with NDMM.

The debate centered on CNS efficacy comparisons between MARIPOSA and FLAURA2, with the key distinction being that MARIPOSA mandated serial brain MRIs for all patients, enabling full intracranial PFS analysis across all 429 participants, whereas FLAURA2 only required serial imaging in patients with baseline CNS metastases, limiting the robustness of its CNS data.

Dr. Zeitouni compares immune-mediated adverse event rates across checkpoint inhibitor agents in advanced CSCC.

Dr. Binod Dhakal leads a discussion on patient selection for BCMA-directed bispecific antibodies in relapsed/refractory multiple myeloma (RRMM), focusing on how these therapies fit within an increasingly complex treatment landscape.

The panel reviews a 58-year-old patient with HR-positive, HER2-negative metastatic breast cancer progressing after endocrine therapy plus CDK4/6 inhibitor treatment. The patient has hepatic and bone metastases with radiographic and symptomatic progression, ECOG performance status 1, controlled hypertension, and mild dry eye syndrome. She prioritizes maintaining professional activity and independence.

Recurrent facial squamous cell cancer with CLL challenges surgery and radiation; experts weigh immunotherapy, cemiplimab data, and patient goals.

Amer Zeidan, MBBS, MD, discusses whether the expanding lower-intensity arsenal has narrowed the definition of a patient with AML who is unfit.

Orca-T is a “big advance” that must be studied further among patients with acute leukemias and myelodysplastic syndromes.

Amer Zeidan, MBBS, MD, discusses how mutation status and physical fitness factor into frontline AML regimen selection.

Whether Orca-T competes with post-transplant cyclophosphamide for GVHD prevention must be studied prospectively, said Wendy Stock, MD.

Amer Zeidan, MBBS, MD, discusses why real-world venetoclax dose modifications do not appear to compromise response durability in AML.

This segment focuses on assessing bleeding and variceal risk before initiating anti-VEGF therapy with atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (HCC).

Dr. Ajai Chari and Dr. Rahul Banerjee review the key efficacy and safety findings from the phase 3 MonumenTAL-3 study in relapsed/refractory multiple myeloma (RRMM).

The panel discusses long-term survival and quality of life with atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (HCC).

Dr. Ajai Chari and Dr. Rahul Banerjee discuss the clinical rationale behind the phase 3 MonumenTAL-3 study and its role in confirming the benefit-risk profile of talquetamab in relapsed/refractory multiple myeloma (RRMM).

The FDA approval of Orca-T represents an “important advance” in the world of allogeneic transplant, according to Wendy Stock, MD.

Jonathan Lee, MD, MSc, and Chinmay Jani, MD, have a candid conversation about what medical training actually feels like.

Amer Zeidan, MBBS, MD, discusses how the newly approved all-oral decitabine/cedazuridine plus venetoclax regimen fits into frontline AML care.

Sivraj Muralikrishnan, MD, analyzed HARMONi-6 safety findings for ivonescimab in NSCLC, addressing VEGF-related toxicities and global generalizability.

Education and reinforcement may improve luspatercept dose titration and persistence in community practice.

Experts weigh CML PCR milestones, urging context over rigid cutoffs when switching TKIs—and keeping treatment‑free remission goals in sight.

Sivraj Muralikrishnan, MD, highlighted top head and neck cancer data from ASCO, including the KEYNOTE-689 trial and the novel mRNA degrader REM-422.

Amer Zeidan, MBBS, MD, and Raji Shameem, MD, discussed sequencing options like luspatercept after ESA failure in RS-negative lower-risk MDS.

Dr. Lipsky addresses the framework for interpreting real-world data and cross-trial comparisons in the absence of head-to-head trials.

Clinicians weigh earlier T‑DXd use in breast cancer by preventing nausea, managing fatigue via dose reductions, and closely monitoring ILD risk in curative settings.

Experts discuss evolving care for HER2-positive metastatic breast cancer brain metastases, highlighting CNS-active drugs, earlier MRI screening, and smarter treatment decisions.